Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
KIORA PHARMACEUTICALS, INC. (KPRX) has a new significant shareholder group reporting on a passive basis under Schedule 13G. Baselake Partners, LP, together with Baselake Management, LLC and David Paolella (collectively, the reporting persons), report beneficial ownership of 257,500 shares of Kiora common stock, representing 5.8% of the class.
The filing explains that the shares are held directly by Baselake Partners, LP, with Baselake Management, LLC as investment manager and David Paolella as managing member. All three reporting persons are deemed to share voting and dispositive power over these shares, but each disclaims beneficial ownership beyond their pecuniary interest. The percentage ownership is calculated based on 4,424,387 shares outstanding as of August 5, 2026, as disclosed in Kiora’s Form 10-Q.
Key Figures
Shares beneficially owned:257,500 sharesPercent of class owned:5.8%Shares outstanding:4,424,387 shares+3 more
6 metrics
Shares beneficially owned257,500 sharesCommon Stock of Kiora Pharmaceuticals reported by Baselake Partners and affiliates
Percent of class owned5.8%Beneficial ownership percentage for each reporting person
Shares outstanding4,424,387 sharesKiora common shares issued and outstanding as of August 5, 2026, per Form 10-Q
Shared voting power257,500 sharesShares over which each reporting person has shared power to vote or direct the vote
Shared dispositive power257,500 sharesShares over which each reporting person has shared power to dispose or direct disposition
Sole voting power0 sharesSole voting power for each of Baselake Partners, Baselake Management, and David Paolella
"Baselake Partners and affiliates report on a passive basis under Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficial ownershipregulatory
"This report shall not be deemed an admission that the Reporting Persons are beneficial owners"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"may be deemed to have shared voting and dispositive power with respect to the Shares"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
dispositive powerfinancial
"shared voting and dispositive power with respect to the Shares owned directly by the Fund"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
pecuniary interestfinancial
"disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in KPRX does Baselake Partners report on this Schedule 13G?
Baselake Partners, LP, Baselake Management, LLC, and David Paolella report beneficial ownership of 257,500 shares of Kiora Pharmaceuticals common stock, representing 5.8% of the outstanding shares, based on 4,424,387 shares outstanding as of August 5, 2026.
Who are the reporting persons in this KPRX Schedule 13G filing?
The reporting persons are Baselake Partners, LP (the fund holding the shares), Baselake Management, LLC (its investment manager), and David Paolella (managing member of the investment manager). They file jointly and may be deemed to share voting and dispositive power over the reported shares.
How many KPRX shares does Baselake Partners have voting and dispositive power over?
Baselake Partners, LP, Baselake Management, LLC, and David Paolella each report 0 shares with sole voting or dispositive power and 257,500 shares with shared voting and shared dispositive power, corresponding to their interests in the fund holding Kiora shares.
On what outstanding share count is Baselake’s 5.8% KPRX ownership based?
The 5.8% beneficial ownership is calculated using 4,424,387 Kiora common shares outstanding as of August 5, 2026, as referenced from Kiora Pharmaceuticals’ Form 10-Q. The reported 257,500 shares are measured against this outstanding share figure.
Do the Baselake reporting persons admit full beneficial ownership of their KPRX shares?
No. The filing states this report shall not be deemed an admission that the reporting persons are beneficial owners of the shares for Section 13 or other purposes, and that each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.
Where is Kiora Pharmaceuticals and the Baselake group based according to this filing?
Kiora Pharmaceuticals’ principal executive offices are at 169 Saxony Rd., Suite 212, Encinitas, California 92024. The Baselake reporting persons list their principal business office at 3155 W. Big Beaver Road, Suite 207, Troy, Michigan 48084.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
KIORA PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
49721T507
(CUSIP Number)
09/10/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
49721T507
1
Names of Reporting Persons
Baselake Partners, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
257,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
257,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
257,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.8 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Please see note in Item 4(a)
SCHEDULE 13G
CUSIP Number(s):
49721T507
1
Names of Reporting Persons
Baselake Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
257,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
257,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
257,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.8 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: Please see note in Item 4(a)
SCHEDULE 13G
CUSIP Number(s):
49721T507
1
Names of Reporting Persons
David Paolella
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
257,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
257,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
257,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.8 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Please see note in Item 4(a)
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
KIORA PHARMACEUTICALS, INC.
(b)
Address of issuer's principal executive offices:
169 Saxony Rd., Suite 212
Encinitas, California 92024
Item 2.
(a)
Name of person filing:
Baselake Partners, LP*
Baselake Management, LLC*
David Paolella*
(b)
Address or principal business office or, if none, residence:
3155 W. Big Beaver Road, Suite 207, Troy, Michigan 48084
(c)
Citizenship:
Baselake Partners, LP - Delaware
Baselake Management, LLC - Delaware
David Paolella - United States of America
(d)
Title of class of securities:
Common Stock, $0.01 par value
(e)
CUSIP Number(s):
49721T507
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Baselake Partners, LP - 257,500*
Baselake Management, LLC - 257,500*
David Paolella - 257,500*
The Common Stock (the "Shares") of KIORA PHARMACEUTICALS, INC. (the "Issuer") reported as of the filing date are held by Baselake Partners, LP (the "Fund"). Baselake Management, LLC serves as the investment manager to the Fund (the "Investment Manager"). David Paolella serves as the managing member of the Investment Manager (the "Managing Member," and collectively with the Fund and the Investment Manager, the "Reporting Persons"). By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Fund. The percentages reported herein are calculated based upon a statement in the Issuer's 10-Q, indicating that there are 4,424,387 Shares issued and outstanding as of August 5, 2026. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Baselake Partners, LP
Signature:
/s/ David Paolella
Name/Title:
David Paolella, Managing Member of Baselake Management, LLC, its investment manager
